ANI Pharmaceuticals (ANIP) announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Egetis Therapeutics AB, a Swedish public company. The total value of the offer is approximately SEK 5.6 billion (approximately $559.9 million). To finance the acquisition and refinance existing debt, ANIP has entered into a new $676 million senior bridge facility.
Key Details
- Offer Terms: The cash offer is for SEK 11.25 per share, SEK 65,750,817 for the convertible loan, and SEK 6.99 per warrant.
- Support & Conditions: Egetis's Board of Directors has unanimously recommended the offer. Shareholders representing approximately 42.2% of Egetis's outstanding shares have provided irrevocable undertakings to accept. The offer is subject to customary conditions, including a minimum tender of at least 90% of Egetis shares.
- Financing: On November 4, 2026, ANIP entered into a credit agreement for a 364-day senior bridge facility of up to $676 million with JPMorgan Chase Bank, N.A. as the administrative agent.